Targeting prolyl endopeptidase with valproic acid as a potential modulator of neutrophilic inflammation

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Roda, Mojtaba Abdul ^a,b   Sadik, Mariam ^a,b   Gaggar, Amit ^b   Hardison, Matthew T ^b   Jablonsky, Michael J ^c   Braber, Saskia ^a   Blalock, James Edwin ^b   Redegeld, Frank A ^b   Folkerts, Gert ^a   Jackson, Patricia L ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; PROLYL ENDOPEPTIDASE; PROLYLGLYCYLPROLINE PEPTIDE; UNCLASSIFIED DRUG; VALPROIC ACID; COLLAGEN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SMOKE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME SUBSTRATE COMPLEX; FEMALE; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; ULTRAVIOLET SPECTROSCOPY; ANIMAL; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEUTROPHIL; SMOKE; TOBACCO;

ANIMALS; COLLAGEN; FEMALE; HUMANS; INFLAMMATION; MICE; NEUTROPHILS; PROTEIN STRUCTURE, SECONDARY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SMOKE; TOBACCO; VALPROIC ACID;

EID: 84901345769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097594     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention (CDC) (2012) Chronic obstructive pulmonary disease among adults - united states, 2011. MMWR Morb Mortal Wkly Rep 61: 938-943.
2. WHO (2008) World health statistics. 2013.
3. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, et al. (2008) A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 180: 5662-5669.
4. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, et al. (2006) A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12: 317-323. 10.1038/nm1361. (Pubitemid 43355080)
5. Hardison MT, Galin FS, Calderon CE, Djekic UV, Parker SB, et al. (2009) The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol 182: 4423-4431. 10.4049/jimmunol.0802457.
6. O'Reilly P, Jackson PL, Noerager B, Parker S, Dransfield M, et al. (2009) N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir Res 10: 38. 10.1186/1465-9921-10-38.
7. O'Reilly PJ, Hardison MT, Jackson PL, Xu X, Snelgrove RJ, et al. (2009) Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen. J Neuroimmunol 217: 51-54. 10.1016/j.jneuroim.2009.09.020.
8. Polgar L (2002) The prolyl oligopeptidase family. Cell Mol Life Sci 59: 349-362.
9. Williams RS, Cheng L, Mudge AW, Harwood AJ (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295. 10.1038/417292a. (Pubitemid 34534711)
10. Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010: 479364.Epub 2010 Jul 29. 10.1155/2010/479364.
11. Thanacoody RH (2009) Extracorporeal elimination in acute valproic acid poisoning. Clin Toxicol (Phila) 47: 609-616. 10.1080/15563650903167772.
12. Cheng L, Lumb M, Polgar L, Mudge AW (2005) How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 29: 155-161. 10.1016/j.mcn.2004.12.003. (Pubitemid 40725606)
13. Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees? Cell Mol Life Sci 64: 2090-2103. 10.1007/s00018-007-7079-x.
14. Wilk S, Orlowski M (1983) Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J Neurochem 41: 69-75. (Pubitemid 13064897)
15. Bellemere G, Morain P, Vaudry H, Jegou S (2003) Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte- stimulating hormone breakdown in the rat brain. J Neurochem 84: 919-929. (Pubitemid 36330646)
16. Shinoda M, Miyazaki A, Toide K (1999) Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav Brain Res 99: 17-25. (Pubitemid 29084523)
17. Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, et al. (1995) Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 58: 217-225.
18. Braber S, Henricks PA, Nijkamp FP, Kraneveld AD, Folkerts G (2010) Inflammatory changes in the airways of mice caused by cigarette smoke exposure are only partially reversed after smoking cessation. Respir Res 11: 99-9921-11-99. 10.1186/1465-9921-11-99; 10.1186/1465-9921-11-99.
19. Hsieh CL, Chen KC, Lin PX, Peng CC, Peng RY (2014) Resveratrol and vitamin E rescued valproic acid-induced teratogenicity the action mechanism. Clin Exp Pharmacol Physiol. 10.1111/1440-1681.12205; 10.1111/1440-1681.12205.
20. Hsieh CL, Chen KC, Ding CY, Tsai WJ, Wu JF, et al. (2013) Valproic acid substantially downregulated genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and pax-3, N-acetylcysteine alleviated most of the induced gene alterations in chicken embryo model. Rom J Morphol Embryol 54: 993-1004.
21. Shen Y, Cai W, Lei S, Zhang Z (2013) Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: A systematic review and meta-analysis. COPD. 10.3109/15412555.2013.858315.
22. Papi A, Ferreri AM, Rocchi P, Guerra F, Orlandi M (2010) Epigenetic modifiers as anticancer drugs: Effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res 30: 535-540.
23. Bakker AV, Jung S, Spencer RW, Vinick FJ, Faraci WS (1990) Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl- prolinal. Biochem J 271: 559-562. (Pubitemid 20344777)
24. Kaszuba K, Rog T, Danne R, Canning P, Fulop V, et al. (2012) Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase. Biochimie 94: 1398-1411. 10.1016/j.biochi.2012.03.012.
25. Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, et al. (2014) Class I HDACs are mediators of smoke-carcinogen induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila). 10.1158/1940-6207.CAPR-13-0254.